Following our list of 50 Companies to Watch in January, we’re back with 10 specifically for the second quarter based on scenarios from Bloomberg Intelligence analysts. The companies in the spotlight span sectors and regions and are part of a larger group of high-confidence Focus Ideas that BI analysts identify on an ongoing basis. Each scenario outlines important catalysts coming in the next few months that support our case.

For more information on BI please visit www.bloomberg.com/bi

Technology

CrowdStrike

Forecast ☀️
The maker of cybersecurity software is positioned to take advantage of increasing demand as more services move into the cloud. —Mandeep Singh
Data Sheet
Market value $51B
Sales, last 12 months $1.5B
Expected 2022 revenue growth, consensus 48%
President/CEO/Co-Founder George Kurtz
Legal name CrowdStrike Holdings Inc.
Triggers

The rise of remote work in the pandemic has boosted demand for cloud computing and the need for CrowdStrike’s products.

Relationships with partners such as Amazon Web Services are helping CrowdStrike increase revenue, which is poised to grow at three times the rate of the broader cybersecurity market through 2025, according to Bloomberg Intelligence.
Calendar
When it reports first-quarter results in June, the company may show that it’s retaining more clients and landing new ones, thanks to its expanding product line.
CrowdStrike could reach $3 billion in annual revenue in 2023, a year earlier than the company’s guidance, according to a BI analysis.
Banking

DNB

Forecast ☀️
The Norwegian bank is set to benefit from Norway’s economic exposure to oil at a time of soaring commodity prices. —Philip Richards
Data Sheet
Market value $36B
Sales, last 12 months $6.5B
Expected 2022 revenue growth, consensus 8%
CEO Kjerstin Braathen
Legal name DNB Bank ASA
Triggers

With oil above $100 a barrel, Norway’s economy is running hotter than others in Europe, supporting expected rate hikes by the central bank.

DNB, Norway’s largest bank by market value, is set to experience stronger lending growth than many European peers.
Calendar
There’s a consensus among analysts for DNB to report first-quarter revenue growth of 10% in April. The bank may also announce a new share buyback program later this year.
Analysts’ 2022 revenue estimates for DNB could rise by at least 2 percentage points, while their expectations for the bank’s peers could drop by the same amount or more, according to a BI analysis.
Oil & Gas

Equinor

Forecast ☀️
The energy company offers investors a hedge against spiraling geopolitical risks and inflationary pressures. —Will Hares
Data Sheet
Market value $119B
Sales, last 12 months $88.7B
Expected 2022 revenue growth, consensus 30%
President/CEO Anders Opedal
Legal name Equinor ASA
Triggers

As the No. 2 natural gas supplier to Europe after Gazprom PJSC, Equinor is poised to gain from market tightness, western sanctions on Russia, and diversification of European energy supply.

The company may report 2022 operating profit that is at least 15% higher than market expectations, according to a BI analysis.
Calendar
Results expected in early May should highlight Equinor’s leverage to rising energy prices and lead analysts to get more bullish on the company.
Biotech

Moderna

Forecast ☁️
As governments scale back efforts to fight Covid-19, they’re unlikely to roll out more broad booster shot campaigns, an idea that has underpinned investor expectations for Moderna and other vaccine makers. —Sam Fazeli
Data Sheet
Market value $72B
Sales, last 12 months $18.5B
Expected 2022 revenue growth, consensus 19%
CEO Stéphane Bancel
Legal name Moderna Inc.
Triggers

Even if additional boosters are approved, uptake is likely to be low, barring a new aggressive variant. That’s based on data showing underwhelming interest in fourth shots in Israel, which is at the forefront of Covid-19 vaccination campaigns.

Analysts’ consensus shows an expectation for Moderna’s 2022-23 vaccine sales to top last year’s $61 billion. That’s too high, according to BI, which finds that 60% to 70% of orders this year could be at risk with campaigns for fourth shots looking unlikely.
Calendar
First-quarter results to come in May should offer more insight on booster orders.
Signs of any new potential variants in the coming months could be key to booster-shot demand.
Pharmaceuticals

Pfizer

Forecast ☀️
With its Paxlovid anti-viral pill, Pfizer is well positioned to minimize severe illness from Covid-19, a key to living with the disease. —John Murphy
Data Sheet
Market value $297B
Sales, last 12 months $81.3B
Expected 2022 revenue growth, consensus 32%
Chairman/CEO Albert Bourla
Legal name Pfizer Inc.
Triggers

If other high-income countries follow the U.S. in ordering Paxlovid to treat Covid in high-risk citizens, the company’s earnings could top market expectations by a wide margin. Pfizer in December increased its 2022 production target to 120 million courses from 80 million, after the drug won U.S. regulatory clearance.

BI calculates that an additional $10 billion in revenue from sales of Paxlovid would boost Pfizer’s earnings per share by almost 14% and add $7 billion in cash. Pfizer in December increased its 2022 production target to 120 million courses from 80 million, after the drug won U.S. regulatory clearance.
Calendar
Pfizer’s first-quarter results in April should offer an important update on Paxlovid orders.
The company’s capacity to manufacture the antiviral pill should increase in the second half of 2022, allowing more shipments.
Property

Sun Hung Kai

Forecast ☁️
With Covid-19 spurring prolonged restrictions in Hong Kong, Sun Hung Kai risks missing its sales targets by a wide margin. —Patrick Wong
Data Sheet
Market value $35B
Sales, last 12 months $10.2B
Expected 2022 revenue growth, consensus 13%
Chairman/Managing Director Raymond Kwok
Legal name Sun Hung Kai Properties Ltd.
Triggers

The city’s zero-Covid policies create big challenges for selling units in Sun Hung Kai’s new Hong Kong projects.

Sun Hung Kai is working on a pair of mass-residential projects in the New Territories and several luxury buildings in Hong Kong, where disappointing sales pose a growing risk.
Calendar
Sales data, particularly for mass residential projects in Tuen Mun and Pak Shek Kok, should be available between March and June and will likely show the impact of the city’s Covid restrictions.
Telecommunications

T-Mobile

Forecast ☀️
Merger benefits and a lead in 5G put T-Mobile in position to boost revenue and earnings from the next generation of mobile networks quicker than U.S. rivals. —John Butler
Data Sheet
Market value $157B
Sales, last 12 months $80.1B
Expected 2022 revenue growth, consensus 2%
President/CEO Mike Sievert
Legal name T-Mobile US Inc.
Triggers

Similar to Verizon Communications Inc.’s dominance in 4G, a combined T-Mobile and Sprint has more capacity and broader coverage in 5G, which may herald a 4 percentage point jump in profit margin, a BI analysis shows.

While 5G isn’t yet living up to hype, T-Mobile looks set to benefit from merger synergies and lower operating costs.
Calendar
First-quarter results in early May are likely to showcase benefits from the Sprint integration.
T-Mobile’s lead in 5G can be assessed in the second quarter following introduction of the service from Verizon and AT&T.
Renewable Energy

Vestas

Forecast ☀️
Sales of wind turbines made by Vestas look set to catch a renewed tailwind as Europe seeks to cut dependence on Russian gas. —Rob Barnett
Data Sheet
Market value $29B
Sales, last 12 months $18.4B
Expected 2022 revenue growth, consensus -6%
President/CEO Henrik Andersen
Legal name Vestas Wind Systems A/S
Triggers

In the wake of surging natural gas prices, wind turbine demand is poised to jump sharply as policies across Europe subsidize a move away from fossil fuels.

The consensus among analysts is for Vestas’s turbine deliveries to remain flat through 2025, but a BI analysis points to 10% annual growth. Service revenue could also grow faster than many expect, as wind power expands.
Calendar
Order backlog and management guidance could spur higher consensus estimates when first-quarter results are released in May.
European governments may announce new measures to accelerate renewable energy deployment around midyear.
Autos

Volkswagen

Forecast ☀️
Electric-vehicle sales growth and the excitement generated by the initial public offering of its iconic Porsche sports car brand augur a hot summer for Volkswagen. —Mike Dean
Data Sheet
Market value $105B
Sales, last 12 months $295.9B
Expected 2022 revenue growth, consensus -1%
CEO Herbert Diess
Legal name Volkswagen AG
Triggers

Battery electric vehicles are the cleanest way forward for cars, and BI expects VW’s EV sales to overtake Tesla Inc.’s by 2024.

VW’s Porsche is quickly electrifying, with 30% of 2023 sales on track to be battery-powered models.
Calendar
First-quarter results, expected in early May, should provide insight into industrywide supply chain issues complicated by Russia’s invasion of Ukraine.
Volkswagen’s June 22nd capital markets day will be focused on battery electric vehicles and software.
An announcement of a Porsche IPO or spinoff could come in the coming months.
Real Estate

Welltower

Forecast ☀️
The real estate investment trust’s housing properties for seniors are positioned to gain growing numbers of residents as the omicron wave subsides in coming months. —Jeff Langbaum
Data Sheet
Market value $42B
Sales, last 12 months $4.7B
Expected 2022 revenue growth, consensus 20%
CEO/Chief Investment Officer Shankh Mitra
Legal name Welltower Inc.
Triggers

Occupancy is critical for Welltower; after dropping significantly during 2020, BI analysis points to a sharp bounce in 2022.

With almost 40% of operating income coming from housing for seniors, Welltower has the most exposure to this segment among health-care REITs. Consensus expects occupancy to reach pre-pandemic levels in 2024; BI thinks this could happen a year earlier.
Calendar
Industry data in early April will show senior housing trends.
Rebounding occupancy could become evident in first-quarter results released in May.

*Market value for each company as of March 28

Photos: Getty Images (7). Courtesy (3)

(Updates with Pfizer’s Paxlovid production target. An earlier version of the story corrected the name of CrowdStrike’s CEO.)

More On Bloomberg

Terms of ServiceTrademarksPrivacy Policy
CareersAdvertise
Ad Choices
Help©2026 Bloomberg L.P. All Rights Reserved.